Catalyst Capital Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

Catalyst Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-87,331	Closed	-$1.6M	–	401
2013 Q4	$1.6M	Buy	+87,331	New	+$1.65M	0.51%	79

Other funds holding RPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Catalyst Capital Advisors's RPRX Position: Q1 2014 in Review

Catalyst Capital Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q1 2014, closing a stake of 87,331 shares — an estimated $1.6M sold.

Catalyst Capital Advisors first reported a position in RPRX in Q4 2013 and held it in 1 quarter. The position peaked at $1.6M in Q4 2013. 80 funds tracked by Wall St. Rank hold RPRX as of Q1 2014.

Catalyst Capital Advisors reported no remaining Repros Therapeutics Inc. position as of Q1 2014 after selling out during the quarter.
Catalyst Capital Advisors sold 87,331 Repros Therapeutics Inc. shares in Q1 2014, an estimated $1.6M.
Catalyst Capital Advisors first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 1 quarter.
Catalyst Capital Advisors's Repros Therapeutics Inc. position peaked at $1.6M in Q4 2013.
80 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2014.

Based on Catalyst Capital Advisors's 13F filing for Q1 2014, filed 12 May 2014.